Still's Disease - Pipeline Insight, 2024

This “Still’s Disease- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Still’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Still’s Disease: Understanding

Still’s Disease: Overview

Still’s Disease is a systemic autoinflammatory disease with a childhood form, known as systemic juvenile idiopathic arthritis (SJIA), and a similar adult form, called adult-onset Still’s Disease (AOSD). The disease is characterized by high spiking fevers, salmon-colored rash that comes and goes, and arthritis. Still's disease accounts for 10%-20% of all cases of juvenile idiopathic arthritis. “Systemic” in the disease means it may affect not only the joints but other parts of the body, including the liver, lungs and heart. Still’s Disease can occur any time during childhood, but it most commonly starts at about two years of age and boys and girls are equally affected.

Symptoms
The symptoms of Still’s Disease include:

• High fevers
• Skin rashes
• Sore throat
• Joint inflammation and pain
• Muscle pain
• Poor appetite

Diagnosis
A diagnosis of Still’s Disease is made based upon a thorough review of current symptoms, medical history and a physical examination. Blood tests can be used to rule out the presence of other diseases with similar symptoms. Tests that can aid in diagnosis include blood tests and x-rays, which reveal changes to the bones or joints, or enlargement to the spleen or liver. Laboratory tests show a marked inflammatory response with leukocytosis (neutrophilia), thrombocytosis, high C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Blood tests may also reveal certain changes associated with Still’s Disease.

Treatment
The initial treatment for Still’s Disease is aimed at controlling the symptoms of joint inflammation, pain and fever through anti-inflammatory drugs. Cortisone medications (steroids) such as prednisone are used to treat more severe features of illness. Methotrexate is often prescribed alongside corticosteroids as it allows lower doses of corticosteroids to be used. Other medicine that are used include hydroxychloroquine, penicillamine, azathioprine, methotrexate, and cyclophosphamide. Recently, biological therapy are in use for the treatment like interleukin 1 blocker anakinra (Kineret), and interleukin 6 blocker Tocilizumab (Actemra). In 2020, the USFDA approved Ilaris (canakinumab) to treat patients with active Still’s Disease, including adult onset Still’s Disease. Some patient may undergo joint replacement surgery in severe cases.

Still’s Disease- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Still’s Disease pipeline landscape is provided which includes the disease overview and Still’s Disease treatment guidelines. The assessment part of the report embraces, in depth Still’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Still’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Still’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Still’s Disease.

Still’s Disease Emerging Drugs Chapters

This segment of the Still’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Still’s Disease Emerging Drugs

Anakinra : Swedish Orphan Biovitrum Anakinra is an interleukin-1 receptor antagonist. In the United States, it is indicated for reduction in signs and symptoms and delaying the progression of structural damage in moderately to severely active rheumatoid arthritis in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs. It is also indicated in the U.S. for the treatment of neonatal-onset multisystem inflammatory disease (NOMID). In October, Sobi randomized the first patient in a Phase III study evaluating the safety and efficacy of the drug for the treatment of Still’s disease. The condition is an auto inflammatory disease, characterized by symptoms like spiking fever, typical transient cutaneous rash, arthritis, lymphadenopathy, hepatosplenomegaly, andserositis.

Camoteskimab: Apollo Therapeutics LtdA Phase Ib/IIa, multicenter, open-label study to evaluate the safety and tolerability, efficacy, pharmacokinetics, and pharmacodynamics of Camoteskimab in subjects with Still's Disease. The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease (Adult Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (sJIA)).

Still’s Disease: Therapeutic Assessment

This segment of the report provides insights about the different Still’s Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Still’s Disease

There are approx. 10+ key companies which are developing the therapies for Still’s Disease. The companies which have their Still’s Disease drug candidates in the most advanced stage, i.e. registration include, Swedish Orphan Biovitrum.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Still’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Still’s Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Still’s Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Still’s Disease drugs.

Still’s Disease Report Insights

• Still’s Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Still’s Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Still’s Disease drugs?
• How many Still’s Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Still’s Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Still’s Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Still’s Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Swedish Orphan Biovitrum
• R-Pharm International, LLC
• Syneos Health
• Apollo Therapeutics Ltd
• AB2 Bio

Key Products

• Anakinra
• RPH-104
• APB-R3
• Camoteskimab

This product will be delivered within 1-3 business days.